BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 26239822)

  • 21. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
    An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
    Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.
    Huang D; Wang H; Liu R; Li H; Ge S; Bai M; Deng T; Yao G; Ba Y
    J Cell Biochem; 2014 Mar; 115(3):549-56. PubMed ID: 24122958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and recurrence pattern in node-negative advanced gastric cancer.
    Lee IS; Yook JH; Kim TH; Kim HS; Kim KC; Oh ST; Kim BS
    Eur J Surg Oncol; 2013 Feb; 39(2):136-40. PubMed ID: 23148932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
    Chen Y; Xia X; Wang S; Wu X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Røe OD; Zhou J
    J Gastroenterol; 2013 Sep; 48(9):1034-44. PubMed ID: 23307041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
    Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
    Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
    Saito M; Kiyozaki H; Takata O; Suzuki K; Rikiyama T
    World J Surg Oncol; 2014 Dec; 12():406. PubMed ID: 25551581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-135a promotes gastric cancer progression and resistance to oxaliplatin.
    Yan LH; Chen ZN; Li-Li ; Chen J; Wei WE; Mo XW; Qin YZ; Lin Y; Chen JS
    Oncotarget; 2016 Oct; 7(43):70699-70714. PubMed ID: 27683111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
    Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
    J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
    Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
    Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
    Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
    Omura T; Shimada Y; Nagata T; Okumura T; Fukuoka J; Yamagishi F; Tajika S; Nakajima S; Kawabe A; Tsukada K
    Oncol Rep; 2014 Feb; 31(2):613-8. PubMed ID: 24317477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
    Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
    Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
    Kim JW; Cho SY; Chae J; Kim JW; Kim TY; Lee KW; Oh DY; Bang YJ; Im SA
    Cancer Res Treat; 2020 Oct; 52(4):1178-1187. PubMed ID: 32599979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.
    Sánchez-Martín D; Otsuka A; Kabashima K; Ha T; Wang D; Qian X; Lowy DR; Tosato G
    J Natl Cancer Inst; 2018 Apr; 110(4):390-399. PubMed ID: 29202196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of HOXA10 promotes gastric cancer cells proliferation and HOXA10(+)/CD44(+) is potential prognostic biomarker for gastric cancer.
    Han Y; Lu S; Wen YG; Yu FD; Zhu XW; Qiu GQ; Tang HM; Peng ZH; Zhou CZ
    Eur J Cell Biol; 2015 Dec; 94(12):642-52. PubMed ID: 26552644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection.
    Wang X; Liu Y; Niu Z; Fu R; Jia Y; Zhang L; Shao D; Du H; Hu Y; Xing X; Cheng X; Li L; Guo T; Li Z; Ji Q; Zhang L; Ji J
    Sci Rep; 2017 Aug; 7(1):7515. PubMed ID: 28790411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.